On this page

Erythromycin

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Erythromycin
Generic name
Erythromycin
Dosage form
Gel
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
4
Packages
6
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Erythromycin 20 mg/g 197650 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Gel
Route of administration
Topical
Presentations
10

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Decreased Sebaceous Gland Activity [PE] PE All 37 members
Macrolide Antimicrobial [EPC] EPC All 31 members
Macrolide [EPC] EPC All 16 members
Macrolides [CS] CS All 32 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
063211
Application type
ANDA · Abbreviated New Drug Application
Approval date
January 29, 1993
Sponsor
PADAGIS US
Products on application
1
Submissions recorded
2
Products approved under application 063211.
Product Trade name Form Strength Ingredient Status TE Flags
063211-001 ERYTHROMYCIN GEL ERYTHROMYCIN Prescription AT RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 063211.
Type No. Action Status Date Review
Supplement 3 Labeling Approved March 31, 2008 —
Original application 1 Approved January 29, 1993 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20230816). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20230816 HUMAN PRESCRIPTION DRUG · 20230717

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Erythromycin Topical Gel USP, 2% is indicated for the topical treatment of acne vulgaris.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Erythromycin Topical Gel USP, 2% should be applied sparingly as a thin film to affected area(s) once or twice a day after the skin is thoroughly cleansed and patted dry. If there has been no improvement after 6 to 8 weeks, or if the condition becomes worse, treatment should be discontinued, and the physician should be reconsulted. Spread the medication lightly rather than rubbing it in. There are no data directly comparing the safety and efficacy of b.i.d. versus q.d. dosing.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Erythromycin Topical Gel USP, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

WARNINGS Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”. After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS In controlled clinical trials, the incidence of burning associated with erythromycin topical gel USP, 2% was approximately 25%. The following additional local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness of the skin have also been reported with the topical use of erythromycin. A generalized urticarial reaction, possibly related to the use of erythromycin, which required systemic steroid therapy has been reported.

Description

openFDA Drug Labeling

DESCRIPTION Erythromycin Topical Gel USP, 2% contains erythromycin (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-Dideoxy-3- C -methyl-3- O -methyl-α-L- ribo -hexopyranosyl)oxy]-14-ethyl-7, 12, 13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6-[[3, 4, 6,-trideoxy-3-(dimethylamino)-β-D- xylo -hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione), for topical dermatological use. Erythromycin is a macrolide antibiotic produced from a strain of Saccaropolyspora erythraea (formerly Streptomyces erythreus ). It is a base and readily forms salts with acids. Chemically, erythromycin is C 37 H 67 NO 13 . It has the following structural formula: Erythromycin has a molecular weight of 733.94. It is a white or slightly yellow, odorless or practically odorless, bitter crystalline powder. Erythromycin is very soluble in very polar organic solvents such as alcohols, acetone, chloroform, acetonitrile and ethyl acetate. It is moderately soluble in less polar solvents such as ether, dichloroethylene and amyl acetate. It is slightly soluble in nonpolar solvents such as hexane. It is very poorly soluble in water. Each gram of Erythromycin Topical Gel USP, 2% contains 20 mg of erythromycin USP in a vehicle consisting of dehydrated alcohol and hydroxypropyl cellulose. Chemical structure

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Erythromycin Topical Gel USP, 2% is available as follows: 60 g sealed metal tube (NDC 63629-8653-1) Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504

Adverse event reports

Source: openFDA FAERS
19,107
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: ERYTHROMYCIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63629-8652-1 63629-8652 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8652-1) / 30 g in 1 TUBE September 8, 2008
63629-8653-1 63629-8653 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8653-1) / 60 g in 1 TUBE June 12, 2008
72162-1444-3 72162-1444 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1444-3) / 30 g in 1 TUBE August 16, 2023
72162-1444-6 72162-1444 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1444-6) / 60 g in 1 TUBE August 16, 2023
45802-966-94 45802-966 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-966-94) / 30 g in 1 TUBE September 8, 2008
45802-966-96 45802-966 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-966-96) / 60 g in 1 TUBE June 12, 2008
63629-8652 63629-8652 Bryant Ranch Prepack — June 12, 2008
63629-8653 63629-8653 Bryant Ranch Prepack — June 12, 2008
72162-1444 72162-1444 Bryant Ranch Prepack — June 12, 2008
45802-966 45802-966 Padagis Israel Pharmaceuticals Ltd — June 12, 2008

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.